These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 392813)

  • 21. Low molecular weight water-soluble peptidoglycans as adjuvants and immunostimulants.
    Jollès P; Migliore-Samour D; Maral R; Floc'h F; Werner GH
    Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(2-4):331-40. PubMed ID: 241167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of M.bovis BCG and M.microti on sarcoma 180 growth in mice.
    Nedvĕdová V; Sír Z; Hyncica V; Buresová M
    Neoplasma; 1978; 25(6):685-90. PubMed ID: 377109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental and clinical trials with BCG immunotherapy.
    Sparks FC; Silverstein MJ; Hunt JS; O'Connell TX; Lee YT; Pilch YH; Haskell CM; Morton DL
    Johns Hopkins Med J Suppl; 1974; 3():103-20. PubMed ID: 4609024
    [No Abstract]   [Full Text] [Related]  

  • 24. The adjuvant effect of n-hexadecane in mouse vaccination tests with heat-killed BCG.
    HOYT A; KNOWLES RG; MOORE FJ; SMITH CR
    Am Rev Tuberc; 1957 Apr; 75(4):624-9. PubMed ID: 13411420
    [No Abstract]   [Full Text] [Related]  

  • 25. Adjuvant activity of mycobacterial fractions. I. Purification and in vivo adjuvant activity of cell wall skeletons of Mycobacterium bovis BCG, Nocardia asteroides 131 and Corynebacterium diphtheriae PW8.
    Azuma I; Kanetsuna F; Taniyama T; Yamamura Y; Hori M
    Biken J; 1975 Mar; 18(1):1-13. PubMed ID: 807194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
    Vaage J
    Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Raw starch microparticles have immunostimulant activity in mice vaccinated with BCG and challenged with Mycobacterium tuberculosis.
    Moreno-Mendieta S; Barrios-Payán J; Mata-Espinosa D; Sánchez S; Hernández-Pando R; Rodríguez-Sanoja R
    Vaccine; 2017 Sep; 35(38):5123-5130. PubMed ID: 28818565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methanol extraction residue fraction of tubercle bacilli (MER) and other mycobacterial extracts as systemic immunity adjuvants in cancer immunotherapy.
    Mathé G; Hiu IJ; Halle-Pannenko O; Bourut C
    Isr J Med Sci; 1976; 12(4-5):468-71. PubMed ID: 820673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of Mycobacterium tuberculosis (BCG) infection on the resistance of mice to bacterial endotoxin and Salmonella enteritidis infection.
    HOWARD JG; BIOZZI G; HALPERN BN; STIFFEL C; MOUTON D
    Br J Exp Pathol; 1959 Jun; 40(3):281-90. PubMed ID: 13662534
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunopotentiation with BCG. 3. Modulation of the response to a tumor-specific antigen.
    Hawrylko E; Mackaness GB
    J Natl Cancer Inst; 1973 Nov; 51(5):1677-82. PubMed ID: 4587142
    [No Abstract]   [Full Text] [Related]  

  • 31. Depression of protective mechanisms against microörganisms in tumor-bearing mice and its restoration by adjuvants.
    Matsuo K; Nomoto K; Shimotori S; Takeya K
    Gan; 1977 Aug; 68(4):465-71. PubMed ID: 99344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adjuvant immunotherapy with BCG for malignant brain tumors (author's transl)].
    Miki Y; Sano K; Takakura K; Mizutani H
    Neurol Med Chir (Tokyo); 1976 Jul; 16(4 pt 2):357-64. PubMed ID: 62316
    [No Abstract]   [Full Text] [Related]  

  • 33. Currents in tuberculosis research.
    Ribi E
    J Infect Dis; 1971 May; 123(5):562-5. PubMed ID: 5000472
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunopotentiation with BCG: dimensions of a specific antitumor response.
    Hawrylko E
    J Natl Cancer Inst; 1975 May; 54(5):1189-97. PubMed ID: 805254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of IFN-gamma producing cells correlates with adjuvant enhancement of bacille Calmette-Guèrin induced protection against Mycobacterium bovis.
    Logan KE; Chambers MA; Hewinson RG; Hogarth PJ
    Vaccine; 2005 Dec; 23(48-49):5526-32. PubMed ID: 16105710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypersensitivity pneumonitis as a complication of intravesical BCG therapy for bladder cancer.
    Carrasco Hernández L; Castaño Núñez ÁL; Rodríguez Portal JA
    Arch Bronconeumol; 2016 Aug; 52(8):445-6. PubMed ID: 26920491
    [No Abstract]   [Full Text] [Related]  

  • 37. Hyperreactivity to endotoxin in mice infected with BCG. Studies on the role of concomitant infection.
    SUTER E
    J Immunol; 1962 Sep; 89():377-81. PubMed ID: 13918520
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of chemical and biological properties of water-soluble adjuvants prepared from Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium smegmatis.
    Kumazawa Y; Shibusawa A; Nakagawa N; Kojima Y; Mizunoe K
    Kitasato Arch Exp Med; 1976 Dec; 49(4):153-62. PubMed ID: 829910
    [No Abstract]   [Full Text] [Related]  

  • 39. [Immunochemistry of tubercle bacilli, with special reference to adjuvant activity (author's transl)].
    Azuma I
    Kekkaku; 1981 Dec; 56(12):595-607. PubMed ID: 7035731
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cancer immunotherapy with BCG cell-wall skeleton (author's transl)].
    Azuma I; Yamamura Y
    Tanpakushitsu Kakusan Koso; 1978 May; 23(6):625-40. PubMed ID: 211546
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.